Moyete (Ethinylestradiol, Gestodene)

Moyete, a combined oral contraceptive, is used to manage reproductive health by preventing ovulation.

• Contraception: prevention of pregnancy in women of childbearing potential.
• Menstrual cycle regulation: helps achieve regular, predictable menstrual bleeding.
• Acne management: may improve mild to moderate acne linked to hormonal fluctuations.
• Endometriosis symptom relief: can reduce dysmenorrhea associated with endometriosis.

• Ethinylestradiol, a synthetic estrogen, binds to estrogen receptors, while gestodene, a progestogen, binds to progesterone receptors. Together they provide negative feedback to the hypothalamic‑pituitary axis, suppressing the release of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). This inhibition prevents follicular development and ovulation. Additionally, gestodene induces cervical mucus thickening and alters the endometrial lining, creating conditions unfavorable for fertilization and implantation.

Moyete may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild stomach upset often occurring at treatment initiation.
• Breast tenderness: temporary swelling or discomfort of the breasts.
• Headache: mild to moderate head pain that may resolve with continued use.
• Breakthrough bleeding: spotting between periods, especially during the first cycles.
• Mood changes: fluctuations in emotional state, such as irritability.
• Weight gain: slight increase in body weight due to fluid retention.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins, potentially life‑threatening.
• Arterial thrombosis: clot formation in arteries, increasing stroke or heart attack risk.
• Hypertension: elevated blood pressure requiring medical monitoring.
• Liver dysfunction: abnormal liver enzymes or jaundice.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Visual disturbances: sudden vision changes or loss requiring urgent care.

Before prescribing Moyete, clinicians should evaluate individual risk factors and contraindications.

• Contraindication: avoid use in women with known thromboembolic disorders, active liver disease, or hormone‑sensitive cancers.
• Smoking: do not use if over 35 years and a smoker, due to increased cardiovascular risk.
• Medication review: assess concurrent use of enzyme‑inducing drugs that may reduce contraceptive efficacy.
• Pregnancy: discontinue immediately if pregnancy is confirmed; product is contraindicated in pregnancy (Category X).
• Store at room temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Moyete may interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin) can markedly reduce contraceptive efficacy.
• Certain antiretrovirals (e.g., efavirenz) may lower hormone levels, increasing pregnancy risk.
• St. John’s wort: herbal inducer that can compromise contraceptive protection.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inducers (e.g., griseofulvin) may modestly decrease effectiveness.
• Antibiotics such as tetracycline may slightly reduce hormone levels.
• Diuretics may affect fluid balance, potentially influencing side‑effect profile.
• Antihypertensives may have reduced effect due to fluid retention.
• Anticonvulsants with enzyme‑inducing properties require careful monitoring.